Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 16/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6127970 | 0.69 | IL2 (0.38) | IL2 | |
| SCHEMBL301247 | 0.65 | ACHE (0.69) | NPC1HPGDTSHRRAB9ASMN1; SMN2 | |
| SCHEMBL29373699 | 0.65 | ACHE (0.69) | NPC1HPGDTSHRRAB9ASMN1; SMN2 | |
| SCHEMBL31471473 | 0.65 | ACHE (0.69) | NPC1HPGDTSHRRAB9ASMN1; SMN2 | |
| SCHEMBL28605783 | 0.65 | L3MBTL1 (0.40) | NOTUMPGRHPGDRAB9A | |
| SCHEMBL9667604 | 0.64 | MAPT (0.49) | NOTUMPGRNPC1HPGDTSHR | |
| SCHEMBL18797759 | 0.63 | ACHE (0.65) | PGRNPC1HPGDTSHRRAB9A | |
| SCHEMBL19577801 | 0.63 | ACHE (0.65) | NPC1HPGDTSHRRAB9ASMN1; SMN2 | |
| SCHEMBL9855192 | 0.62 | NISCH (0.53) | NOTUMPGRNPC1RAB9A | |
| SCHEMBL1338857 | 0.62 | KDM4E (0.56) | IL2PGRNPC1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2017-10-26 | — | — | US | disclosed |
| US-9737534-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-22 | — | — | US | disclosed |
| US-9737534-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-22 | — | — | US | disclosed |
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-01-28 | — | — | US | disclosed |
| US-9169242-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2015-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | RYR2, RYR1, GABRR1 | IL2 2413/4885NOTUM 3543/4885PGR 2525/4885 |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | RYR2, ADRA2C, RYR1 | IL2 2980/4885NOTUM 4113/4885PGR 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.